Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Drug Profile

Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Alternative Names: ARC AMG1; ARC HIF2; ARC-F12; ARO APOC3; ARo Lung1; ARO-AMG1; ARO-ENaC; ARO-F12; ARO-Lung1

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mirus Bio Corporation
  • Developer Arrowhead Pharmaceuticals; Roche Madison
  • Class Antifibrotics; Antihyperlipidaemics; Antineoplastics; Antithrombotics; Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action ANGPTL3 protein inhibitors; Apolipoprotein C-III inhibitors; Endothelial PAS domain-containing protein 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Cystic fibrosis; Hereditary angioedema; Hypertriglyceridaemia; Liver cancer; Lung cancer; Renal cell carcinoma; Solid tumours; Thromboembolism
  • No development reported Hyperlipidaemia; Respiratory tract disorders

Most Recent Events

  • 07 Jan 2019 Arrowhead Pharmaceuticals files a clinical trial application (CTA) for ARO-APOC3 with the local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for Hypertriglyceridemia
  • 03 Dec 2018 Arrowhead Pharmaceuticals plans a phase I AROANG1001 trial for ARO ANG3 in Hypertriglyceridaemia, Dyslipidaemias and Hypercholesterolaemia (In volunteers) (SC) in December 2018 (NCT03747224)
  • 16 Oct 2018 Arrowhead plans the phase I single and multiple ascending dose AROANG1001 trial for ARO APOC3 for Hypertriglyceridaemia in February 2019 (SC) (NCT03783377)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top